Cipla announces its Q4 FY20 results demonstrating sustained growth momentum across core businesses and unlocking of respiratory pipeline Kumar Jeetendra | May 15, 2020 Mumbai, May 15, 2020: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its audited consolidated financial results for quarter ended March 31st, 2020. Key highlights of the quarter: India: The Rx business grew by 12% on a y-o-y basis recording a 3rd consecutive quarter of market beating growth. The trade Gx business revives strongly recording …
Cipla expands partnership with Roche Pharma India to further improve access to key oncology medicines Kumar Jeetendra | June 18, 2020 Mumbai 18th June 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) and Roche Products (India) Pvt. Ltd. (Roche Pharma) today announced that the two companies have entered into an agreement to provide better access to innovative medicines for patients in India. Under this agreement, Cipla will be responsible for …
Cipla dispatches nonexclusive rendition of remdesivir in India Kumar Jeetendra | July 9, 2020 Pharma important Cipla on Wednesday said it has launched its own generic version of antiviral drug remdesivir at a cost which is one of the lowest internationally and is seeking to supply over 80,000 vials over the first month. The company, however, did not disclose the purchase price of the medicine. Cipla had earlier said …
Cipla receives final approval for generic version of Shire’s Firazyr® Kumar Jeetendra | July 14, 2020 Mumbai, India; July 14, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA). Cipla’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated …
Cipla receives final approval for generic version of GlaxoSmithKline’s IMITREX® (Sumatriptan Nasal Spray, 20 mg) Kumar Jeetendra | March 2, 2021 Mumbai, India, March 02, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ hereinafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug Administration (U.S. FDA). Cipla’s Sumatriptan Nasal Spray USP, 20 mg …
Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats Kumar Jeetendra | March 23, 2021 March 23, 2021, MUMBAI – Cipla Therapeutics, an affiliate of Cipla Limited (BSE: 500087; NSE: CIPLA EQ; referred to as “Cipla”) and SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market announced entering into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly …
Cipla and Kemwell Biopharma announce execution of a joint venture agreement for developing, manufacturing and commercialising biosimilars Kumar Jeetendra | August 25, 2021 Mumbai, India, August 25, 2021: Cipla Limited (BSE: 500087 | NSE: CIPLA EQ, hereafter referred to as “Cipla”), a leading global pharmaceutical company and Kemwell Biopharma Private Limited, a leading biopharmaceutical Contract Development and Manufacturing Organisation (CDMO), announced execution of a joint venture agreement to develop, manufacture and commercialise biosimilars for global markets. For this …
Cipla ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Emerging Markets Index Kumar Jeetendra | November 15, 2021 Mumbai, India; November 15, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has been selected in the S&P Dow Jones Sustainability Index (DJSI) for the Emerging Markets for 2021. The DJSI family of indices is operated by one of the world’s leading index providers S&P …
Cipla Health signs agreement to acquire Endura Mass Kumar Jeetendra | July 14, 2022 Mumbai, India; July 14, 2022: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Company” or “Cipla”) announced today that Cipla Health Limited (CHL), wholly owned subsidiary and consumer healthcare arm of the Company has signed definitive agreements for acquisition of Endura Mass, a renowned nutritional supplement brand in the category of …
Cipla launches CIPLAMED 2.0 – knowledge-sharing platform for Healthcare Practitioners (HCPS) Kumar Jeetendra | August 16, 2023 Mumbai, India; 16th August 2023: Cipla announced the launch of CiplaMed 2.0, an enhanced version of the industry-leading knowledge platform for the medical fraternity. In line with its digital transformation agenda, Cipla is pioneering an integrated omnichannel experience for healthcare professionals that seamlessly combines in-clinic interactions with digital engagement and access to medical information. This …
